Please login to the form below

rovalpituzumab tesirine

This page shows the latest rovalpituzumab tesirine news and features for those working in and with pharma, biotech and healthcare.

Rova-T (rovalpituzumab tesirine) consists of an anti-DLL3 antibody linked to a cancer-killing agent called pyrrolo-benzodiazepine.

European biosimilars hit AbbVie’s Humira revenues in Q4

The fate of its Rovalpituzumab Tesirine (Rova-T) also hangs in the balance after it failed in a phase 3 trial for small cell lung cancer in December.
AbbVie slumps on trial results for would-be blockbuster Rova-T

The fall-off is no surprise given that AbbVie has spent the last few months building up expectations for antibody-drug conjugate Rova-T (rovalpituzumab tesirine), pointing to its blockbuster sales
Trial of AbbVie's Rova-T disappoints at ASCO

The antibody drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) achieved a modest improvement in a first-in-man trial in recurrent small cell lung cancer (SCLC), a disease with a notoriously
AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

The acquisition will give AbbVie access to Stemcentrx's pipeline of five drugs in clinical trials, including a lead candidate called rovalpituzumab tesirine (rova-T) for small cell lung cancer (SCLC)

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Deal Watch April 2016

Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...